Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 [Yahoo! Finance]
Curis, Inc. (CRIS)
Last curis, inc. earnings: 11/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.curis.com
Company Research
Source: Yahoo! Finance
orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024 , at 8:00 a.m. ET . Management will host a conference call on the same day at 8:30 a.m. ET To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call. About Curis, Inc. Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a
Show less
Read more
Impact Snapshot
Event Time:
CRIS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRIS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRIS alerts
High impacting Curis, Inc. news events
Weekly update
A roundup of the hottest topics
CRIS
News
- Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $26.00 price target on the stock.MarketBeat
- Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.MarketBeat
- Curis, Inc. (NASDAQ: CRIS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Curis Announces Additional Data from TakeAim Leukemia Study [Yahoo! Finance]Yahoo! Finance
- Curis Announces Additional Data from TakeAim Leukemia StudyPR Newswire
CRIS
Earnings
- 5/7/24 - Miss
CRIS
Sec Filings
- 5/14/24 - Form 8-K
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- CRIS's page on the SEC website